Cocrystal Pharma, Inc. COCP
Pharma, Inc. (the "Company" or "Cocrystal") is a clinical-stage biotechnology company discovering and developing
novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and
Nobel Prize winning expertise with the goal of creating viable antiviral drugs. These technologies are designed to efficiently deliver
small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $2.0M | $6.6M | — | — | — |
| R&D | $5.1M | $12.5M | $15.2M | $12.4M | $8.8M | $6.0M | $4.0M | $4.7M | $5.8M | $101.7M |
| SG&A | $4.0M | $5.3M | $6.0M | $5.7M | $5.4M | $5.6M | $4.9M | $4.4M | $2.4M | $4.1M |
| Total operating expenses | $9.0M | $17.9M | $18.6M | $38.8M | $14.2M | $11.6M | $55.0M | $62.9M | $8.3M | $105.8M |
| Operating income | -$9.0M | -$17.9M | -$18.6M | -$38.8M | -$14.2M | -$9.6M | -$48.4M | -$62.9M | -$8.3M | -$105.8M |
| Interest expense | $134.0K | $537.0K | $640.0K | $2.0K | $4.0K | $8.0K | $19.0K | $58.0K | $7.0K | — |
| Pre-tax income | -$8.8M | -$18.6M | — | — | — | -$9.6M | -$48.2M | -$62.6M | -$7.5M | -$104.3M |
| Income tax | — | — | — | — | — | — | — | $13.6M | $6.9M | $29.4M |
| Net income | -$8.8M | -$17.5M | -$18.0M | -$38.8M | -$14.2M | -$9.6M | -$48.2M | -$49.0M | -$613.0K | -$74.9M |
| EPS, basic | -0.78 | -1.72 | -1.87 | -4.77 | -0.16 | — | — | — | -0.03 | -3.18 |
| EPS, diluted | -0.78 | -1.72 | -1.87 | -4.77 | -0.16 | -0.17 | -1.51 | -1.75 | -0.03 | -3.30 |
| Shares, diluted (wtd. avg.) | $11.3M | $10.2M | $9.7M | $8.1M | $7.4M | — | $31.9K | $28.0K | $24.1M | $23.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.0M | $9.9M | $26.4M | $37.1M | $58.7M | $33.0M | $7.4M | — | $748.0K | $3.6M |
| Receivables | — | — | — | — | — | $556.0K | $644.0K | — | $1.0K | $21.0K |
| Total current assets | $8.1M | $11.6M | $29.1M | $40.2M | $59.3M | $34.0M | $8.3M | $2.9M | $2.2M | $5.5M |
| Property, plant and equipment | $93.0K | $153.0K | $271.0K | $342.0K | $453.0K | $591.0K | $431.0K | $384.0K | $119.0K | $280.0K |
| Goodwill | — | — | — | — | $19.1M | $19.1M | $19.1M | $65.2M | $65.2M | $65.2M |
| Total assets | $9.7M | $13.5M | $31.3M | $40.8M | $79.4M | $54.2M | $28.5M | $68.6M | $121.4M | $124.9M |
| Accounts payable | $890.0K | $1.5M | $1.2M | $614.0K | $578.0K | $657.0K | $1.5M | $616.0K | $494.0K | $563.0K |
| Total current liabilities | $2.2M | $2.4M | $3.3M | $1.2M | $1.5M | $1.4M | $2.3M | $1.6M | $1.4M | $2.0M |
| Total liabilities | $3.4M | $3.9M | $4.9M | $1.3M | $1.8M | $1.7M | $2.8M | $1.7M | $16.0M | $22.6M |
| Retained earnings | -$342.2M | -$333.4M | -$315.9M | -$297.9M | -$259.1M | -$244.9M | -$235.3M | -$187.1M | -$138.0M | -$137.4M |
| Total equity | $6.3M | $9.5M | $26.4M | $39.6M | $77.5M | $52.5M | $25.7M | $66.9M | $105.4M | $102.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.2M | -$16.5M | -$14.7M | -$21.4M | -$12.7M | -$9.8M | -$1.6M | -$8.3M | -$6.9M | -$14.7M |
| Depreciation and amortisation | — | — | — | — | — | — | — | $50.0K | $101.0K | $201.0K |
| Stock-based compensation | $270.0K | $643.0K | $801.0K | $855.0K | $724.0K | $662.0K | $351.0K | $562.0K | $614.0K | $548.0K |
| Capital expenditure | $12.0K | $8.0K | $118.0K | $74.0K | $52.0K | $240.0K | $145.0K | $28.0K | $40.0K | $51.0K |
| Investing cash flow | -$12.0K | -$8.0K | -$118.0K | -$74.0K | -$52.0K | -$240.0K | -$145.0K | $1.4M | -$40.0K | $3.0K |
| Financing cash flow | $5.4M | — | $4.0M | -$27.0K | $38.5M | $35.7M | $6.4M | $8.9M | $4.1M | $9.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-025428.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |